CXCL14: A Potential Drug Target and Biomarker for Cancer (G9547)

Target Name: CXCL14

NCBI ID: G9547

CXCL14

CXCL14: A Potential Drug Target and Biomarker for Cancer

CXCL14, also known as bolekine, is a protein that is expressed in various tissues throughout the body, including the heart, lungs, kidneys, and intestines. It is a member of the CXCR1 family, which includes other proteins that play a critical role in the regulation of cell-cell interactions and signaling.

One of the key functions of CXCL14 is its role in the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to tissues. CXCL14 has been shown to promote the formation of new blood vessels in various tissues, including the lungs and the kidneys.

In addition to its role in angiogenesis, CXCL14 has also been shown to play a critical role in the regulation of immune responses and inflammation. It has been shown to attract immune cells to sites of injury or infection, which helps to protect the body against the harmful effects of these processes.

CXCL14 has also been shown to play a role in the regulation of cell signaling, particularly in the signaling pathway known as the TGF-β pathway. This pathway is involved in the regulation of cell growth, differentiation, and inflammation, and is a key factor in the development and maintenance of many diseases, including cancer.

Given its widespread presence and its critical functions, CXCL14 has become a focus of interest for researchers as a potential drug target or biomarker. Many studies have been conducted to investigate the effects of drugs that target CXCL14, with the goal of using these drugs to treat a variety of diseases.

One of the most promising areas of research is the use of CXCL14 as a drug target for cancer. Many studies have shown that CXCL14 is highly expressed in various tissues of cancer cells, and that it plays a critical role in the regulation of cancer cell growth and survival.

For example, one study published in the journal PLoS Medicine found that inhibiting CXCL14 using a small molecule inhibitor reduced the growth and survival of cancer cells. Another study published in the journal Oncology Reports found that CXCL14 was a strong predictor of cancer patient survival, and that inhibiting it using a small molecule inhibitor improved survival outcomes in these patients.

In addition to its potential as a cancer drug target, CXCL14 has also been shown to be a potential biomarker for the disease. Its expression has been shown to be elevated in a variety of tissues and conditions, including cancer, heart disease, and respiratory tract infections.

One of the key advantages of using CXCL14 as a biomarker for cancer is its ability to be easily measured and detected in a variety of settings, such as blood, urine, and tissue samples. This makes it an attractive option for the development of diagnostic tests for cancer, as well as for monitoring the effectiveness of treatments.

Another promising application of CXCL14 as a biomarker for cancer is its potential to be used in personalized medicine. By using CXCL14 as a biomarker to predict which treatments will be most effective for individual patients, doctors can tailor treatments to specific needs and improve outcomes.

Overall, CXCL14 is a protein that has important functions in the regulation of angiogenesis, immune responses, and cell signaling, and has been shown to be involved in a variety of diseases, including cancer. As a result, it is an attractive target for drug development and a potential biomarker for the treatment of these diseases. Further research is needed to fully understand the role of CXCL14 in these processes and to develop effective treatments.

Protein Name: C-X-C Motif Chemokine Ligand 14

Functions: Potent chemoattractant for neutrophils, and weaker for dendritic cells. Not chemotactic for T-cells, B-cells, monocytes, natural killer cells or granulocytes. Does not inhibit proliferation of myeloid progenitors in colony formation assays

The "CXCL14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CXCL14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets